Windisch et al., 2007 - Google Patents

Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders?

Windisch et al., 2007

Document ID
3168182105298121796
Author
Windisch M
Wolf H
Hutter-Paier B
Hofmeister A
Wronski R
Publication year
Publication venue
Current Alzheimer Research

External Links

Snippet

Alpha-synuclein is the main constituent of intra-neuronal Lewy bodies, which are characteristic of Parkinson's disease, but aggregates are also found as axonal inclusions. Alpha-synuclein pathology is found together with betaamyloid plaques and neurofibrillary …
Continue reading at www.ingentaconnect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Similar Documents

Publication Publication Date Title
Stroo et al. Cellular regulation of amyloid formation in aging and disease
Chung et al. Cellular and pathological heterogeneity of primary tauopathies
Navarro et al. Microglia in Alzheimer’s disease: activated, dysfunctional or degenerative
Castillo-Carranza et al. α-Synuclein oligomers induce a unique toxic tau strain
Swerdlow Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease
Reddy Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer's disease
Gendron et al. The role of tau in neurodegeneration
Wen et al. Cdk5 is involved in NFT-like tauopathy induced by transient cerebral ischemia in female rats
Castelvetri et al. Axonopathy is a compounding factor in the pathogenesis of Krabbe disease
Gong et al. Dysregulation of protein phosphorylation/dephosphorylation in Alzheimer′ s disease: a therapeutic target
Buttini et al. Expression of human apolipoprotein E3 or E4 in the brains ofApoE−/− mice: Isoform-specific effects on neurodegeneration
Li et al. The role of the LRRK2 gene in Parkinsonism
Schlossmacher et al. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies
Chen et al. Lysosomal exocytosis in Schwann cells contributes to axon remyelination
Mullin et al. α-Synuclein and mitochondrial dysfunction in Parkinson’s disease
Kanaan et al. Loss of functional alpha-synuclein: a toxic event in Parkinson's disease?
Head et al. Small heat shock proteins, the cytoskeleton, and inclusion body formation
Yu et al. α-Synuclein and dopamine metabolism
Eschbach et al. α-Synuclein in Parkinson's disease: pathogenic function and translation into animal models
Berry et al. Pathological glial tau accumulations in neurodegenerative disease: review and case report
KR20210113606A (en) Methods for detecting, preventing, recovering and treating neurological disorders
Parra Bravo et al. Cellular and pathological functions of tau
von Bohlen und Halbach Synucleins and their relationship to Parkinson’s disease
Windisch et al. Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders?
Emilien et al. Alzheimer disease: neuropsychology and pharmacology